BRANDS OF KETOROLAC EYE DROPS IN KENYA
Acular®,Allergan Pharmaceuticals (Pty) Ltd
Ketolac® , Aurolab
Lopadol®, Popular Pharmaceuticals Limited
MODE OF ACTION OF KETOROLAC TROMETAMOL (Opthalmic)
Ketorolac is a non-steroidal anti-inflammatory agent demonstrating analgesic and anti-inflammatory activity. Ketorolac trometamol inhibits the cyclo-oxygenase enzyme essential for biosynthesis of prostaglandins.Ketorolac has been shown to reduce prostaglandin levels in the aqueous humour after topical ophthalmic administration.
INDICATIONS:
Ketorolac is indicated for the prophylaxis and reduction of inflammation and associated symptoms following ocular surgery.
CONTRAINDICATIONS:
Hypersensitivity to the active substance(s) or to any of the excipients
The potential exists for cross-sensitivity to acetylsalicylic acid and other non-steroidal anti-inflammatory drugs.Ketorolac is contraindicated in individuals who have previously exhibited sensitivities to these drugs.
DRUG INTERACTIONS
No interaction studies have been performed.
Ketorolac trometamol has been safely administered with systemic and ophthalmic medications such as antibiotics, sedatives, beta blockers, carbonic anhydrase inhibitors, miotics, mydriatics, local anaesthetics and cycloplegics.
Ketorolac trometamol may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical corticosteroids may increase the potential for healing problems
ADVERSE DRUG REACTIONS:
Immune system disorders
Common: Hypersensitivity including localised allergic reactions
Nervous system disorders
Common: Headache
Eye Disorders
Very Common:
Eye irritation (including burning sensation)
Eye pain (including stinging)
Common:
Superficial (punctate) keratitis
Eye and/or eyelid oedema
Ocular pruritus
Conjunctival hyperaemia
Eye infection
Eye inflammation
Iritis
Keratic precipitates
Retinal haemorrhage
Cystoid macular oedema
Eye trauma
Increased intraocular pressure
Blurred and/or diminished vision
Uncommon:
Corneal ulcer
Corneal infiltrates
Eye dryness
Epiphora
Not known:
Corneal damage, e.g. thinning, erosion, epithelial breakdown and perforation*
ulcerative keratitis
eye swelling
ocular hyperaemia
Respiratory, thoracic and mediastinal disorders
Not known:
Bronchospasm or exacerbation of asthma
Reporting of suspected adverse reactions:
The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, pv@pharmacyboardkenya.org or clicking below button:
Ketorolac eye drops in Kenya
Ketorolac eye drops in Kenya
Ketorolac eye drops in Kenya
Ketorolac eye drops in Kenya
Clinical | Pharmacokinetic data
Pregnancy Category:
Routes of Administration: Opthalmic
Bioavailability: Not AvailableAcular®
Protein Binding: Not Available
Metabolosim: Not Available
Onset of Action:
Elimination Half life: Not Available
Excretion: Not Available
Legal Status | Dosage forms & Strengths
Prescription Category:
Prescription only Medicine (POM) , ℞-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:
Eye drop
Drug Indentifiers:
CAS Number | |
---|---|
PubChem | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) |
Drug Images
References/ Citation:
- “Ketorolac Tromethamine Monograph for Professionals”. Drugs.com. American Society of Health-System Pharmacists.
- British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 1144, 1302–1303